Related Experiment Video

Updated: Jul 4, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Neurotoxicity with blinatumomab in combination with intrathecal methotrexate therapy

Sandy On1, Eric Kuo2, Kimberly M Lau1

  • 1Department of Pharmacy, Stanford Health Care, Stanford, CA, USA.

Leukemia & Lymphoma
|November 1, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
acute lymphoblastic leukemiablinatumomabintrathecal methotrexateneurotoxicity

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Jul 4, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Articles linked to this work by shared authors, journal, and citation graph.

Treatment of lymphoma with rituximab and chemotherapy during pregnancy.

Leukemia & lymphoma·2022

Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.

British journal of haematology·2022

Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2020

Evaluation of pharmacist interventions in a head and neck medical oncology clinic.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2020

Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2019

Incidence of clinically significant chemotherapy induced nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis.

Leukemia & lymphoma·2026

The roles of RUNX1 in megakaryocyte differentiation in myeloid leukemia.

Leukemia & lymphoma·2026

Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis.

Leukemia & lymphoma·2026

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Leukemia & lymphoma·2026

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Leukemia & lymphoma·2026

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Leukemia & lymphoma·2026

Research Progress of Molecular H2 in Mediating Immune Tolerance via Regulating Tregs-from the Perspective of the 2025 Nobel Prize in Physiology or Medicine.

Drug design, development and therapy·2026

Reversing zinc dyshomeostasis and oxidative stress: A metallothionein 1-activating MXene/Zn2+ triple-action nanotherapeutic strategy for chronic non-bacterial prostatitis.

Bioactive materials·2026

Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.

Expert review of vaccines·2026

Therapeutic Potential and Toxicological Impact of Graphene Quantum Dot Nanocomposites in Adult Zebra Fish.

Applied biochemistry and biotechnology·2026

Cardiac involvement in Wilson disease: pathophysiology, clinical spectrum, and multimodality imaging assessment.

Frontiers in cardiovascular medicine·2026

Efficacy of Vibegron in Overactive Bladder: A Bayesian Cross-Trial Synthesis of Benefit Probabilities and Decision Thresholds.

Lower urinary tract symptoms·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us